Problems logging in

Onco'Zine - The International Cancer Network

Onco’Zine is raising awareness of the impact of cancer, cancer diagnosis and treatment an publishes a broad range of topics and timely news.

Pramod Kumar Bile Duct Cancer Therapeutics Market Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2024
Bile duct cancer is also known as cholangiocarcinoma. It involves the presence of mutated epithelial cells originated in the bile ducts. However, the cause of bile duct cancer (cholangiocarcinoma) is not certain. There are some factors that can increase the chances of developing bile duct cancer (cholangiocarcinoma).
Download Free Sample copy of this Research Report
http://bit.ly/bile-duct-cancer-therapeutics-market-s
The bile duct cancer treatment market has significant unmet need, due to the safety profiles and inadequate efficacy of the existing market products. Therefore, the market offers vast potential for novel participants that can introduce drugs, which could reverse or halt the disease progression and simultaneously, offer good safety profiles and high efficacy.
The global bile duct cancer therapeutics market has been classified on the basis of disease indication, treatment type and geography. Based on disease indication, the global bile duct cancer therapeutics market has been segmented into perihilar (hilar) bile duct cancers, distal bile duct cancers, and intrahepatic bile duct cancers. Based on treatment type, the global bile duct cancer therapeutics market has been segmented into chemotherapy, chemoradiation and stent insertion. Based on region, the global market has been segmented into Latin America, North America, Asia-Pacific, Middle East & Africa, and Europe.
Geographically, North America has been the largest market for bile duct cancer therapeutics. The growth of the regional market can be attributed to adequate reimbursement policies, greater awareness toward health care and advanced healthcare facilities. The Asia-Pacific and European markets for bile duct cancer therapeutics are projected to record strong CAGRs, over the forecast period.
Only visible to XING members Eye Cancer Market to 2027 - Global Analysis and Forecasts by Type (Eyelid Tumor, Corneal Tumor, Uveal Melanoma, Orbital Tumor)
Get sample PDF copy @ http://bit.ly/2X8pv3X
Eye cancer refers to any type of cancer that starts in the eye. Cancer starts when the cells begin to grow out of control. The most common type of cancer occurring in the eye is melanoma, however there are various types of cancer that affect the other parts of the eyes. The eye cancer is a very uncommon type of cancer that can affect three parts of the eye that includes eyeballs, orbit and adnexal.
The eye cancer market is anticipated to grow in the forecast, owing to the factors such as increasing incidence of eye cancers, rising healthcare expenditure, and increasing geriatric population. In addition, initiatives undertaken by various government and non-government organizations for research and investment into eye cancer therapeutics is expected to offer significant growth opportunities in the market during the forecast period.
The Emerging/Prominent key players include in this research are: Novartis AG, Spectrum Pharmaceuticals, GlaxoSmithKline, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, AstraZeneca, F. Hoffmann-La Roche, Sanofi, Takeda Pharmaceuticals.
Monika Singh Testicular Cancer Therapeutics Market by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape
Global testicular cancer therapeutics market is growing with the increasing prevalence of testicular cancer. The market is expected to witness moderate growth, since there are already more than 15 drugs that exist in the market for the treatment of testicular cancer. Increasing prevalence of cancer and rising demand for the medications with better efficacy and less side effects can be attributed as an opportunity for oncology. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing increased funding, designations and grants for speeding up the drug development process.
Download Free PDF Sample Copy of Report : http://bit.ly/testicular-cancer-therapeutics-s
Diagnosis of testicular cancer is done through a blood test, ultrasound and biopsy. Also, the type of testicular cancer is determined with the diagnosis along with its stage. There are two types of testicular cancer- seminoma testicular cancer and non- seminoma testicular cancer. After the diagnosis, the treatment options are selected according to the stage and the type of testicular cancer. The treatment options that are available to the patients are chemotherapy, radiation therapy and surgery. Surgery include orchidectomy, removal of both the testicles, lymph node surgery and hormone replacement therapy.
Growing prevalence of testicular cancer and combination therapies for the treatment are the major driving forces for the testicular cancer therapeutics market. Also with no drug in Phase III, there is a need for growth in pipeline for better treatment options, providing increased opportunities to the players in the market.
Some of the marketed drugs for the treatment of testicular cancer include Blenoxane (Bleomycin), Cisplatin, Cosmegen (Dactinomycin), Cyfos (Ifosfamide), Etopophos (Etoposide Phosphate) and Velban (Vinblastine Sulfate). Some of the drug combination available in the market are BEP, JEB, PEB, VIP and VeIP.
Some of the key players operating in the global testicular cancer therapeutics market are Ovation Pharmaceuticals, Inc., ZIOPHARM Oncology Inc., Bristol-Myers Squibb Company, Hospira Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG and Teva Parenteral Medicines, Inc.
Raguwar Singh Bile Duct Cancer Therapeutics Market - Analysis by Stages, Drug Class, Company Profile, Phase of Development, Clinical Trial & Discovery Stage Insights
Bile duct cancer is also known as cholangiocarcinoma. It involves the presence of mutated epithelial cells originated in the bile ducts. However, the cause of bile duct cancer (cholangiocarcinoma) is not certain. There are some factors that can increase the chances of developing bile duct cancer (cholangiocarcinoma).
Download Free Sample copy of this Research Report: http://bit.ly/bile-duct-cancer-therapeutics-market-s
The most common symptoms of bile duct cancer (cholangiocarcinoma) include abdominal pain, abnormal liver function, generalized itching, weight loss, discoloration of stool and urine, etc. The risk factor of bile duct cancer (cholangiocarcinoma) include liver fluke infections, cholangitis and exposure to thorium dioxide. According to American Society of Clinical Oncology (ASCO), less than 3,000 people are affected with the disease, every year, in the U.S. Also, according to Cancer Research UK, about 1,600 people are affected by the disease, every year, in the U.K. The existing treatment options for bile duct cancer (cholangiocarcinoma) are mainly dominated by generics and off-label drugs, and provide only symptomatic relief.
The global bile duct cancer therapeutics market has been classified on the basis of disease indication, treatment type and geography. Based on disease indication, the global bile duct cancer therapeutics market has been segmented into perihilar (hilar) bile duct cancers, distal bile duct cancers, and intrahepatic bile duct cancers. Based on treatment type, the global bile duct cancer therapeutics market has been segmented into chemotherapy, chemoradiation and stent insertion. Based on region, the global market has been segmented into Latin America, North America, Asia-Pacific, Middle East & Africa, and Europe.
Geographically, North America has been the largest market for bile duct cancer therapeutics. The growth of the regional market can be attributed to adequate reimbursement policies, greater awareness toward health care and advanced healthcare facilities. The Asia-Pacific and European markets for bile duct cancer therapeutics are projected to record strong CAGRs, over the forecast period.
Some of the key players in the global bile duct cancer therapeutics market include, Bayer, AG, Delcath Systems Inc., Senhwa Biosciences, Inc., PCI Biotech, Inc., ASLAN Pharmaceuticals, Inc., RedHill Biopharma Ltd. and Halozyme Therapeutics, Inc. among several others.

Moderators

Moderator details

About the group: Onco'Zine - The International Cancer Network

  • Founded: 17/01/2011
  • Members: 33
  • Visibility: open
  • Posts: 27
  • Comments: 0